ASXUpdate - Proposed issue of securities - PTX
other announcement
Prescient Therapeutics (PTX) News
Latest articles and price-sensitive announcements with AI sentiment classification.
Prescient Therapeutics - Extension of Share Purchase Plan
capital_raise announcement
StockheadPrescient advances first-in-class cancer drug as big pharma shops for deals
PTX-100 is now in a Phase 2a trial for cutaneous T-cell lymphoma, a rare form of blood cancer with limited ... Read More The post Prescient advances first-in-class cancer drug as big pharma shops for deals appeared first on Stockhead.
Prescient lymphoma drug trial hits key review milestone
Prescient has reached the enrolment threshold that will trigger the first dose optimisation review of its Phase 2a PTX-100 trial ... Read More The post Prescient lymphoma drug trial hits key review milestone appeared first on Stockhead.
PTX-100 CTCL Phase 2a study reaches review milestone
other announcement
KalkineWhat’s Next for Prescient Therapeutics (ASX:PTX) After Capital Raise?
Highlights Prescient Therapeutics has opened a capital raising initiative to help fund its lead cancer therapy program. Proceeds are earmarked for advancing an ongoing clinical study targeting hard-to-treat blood and solid tumour cancers. Regulatory designations secured in overseas markets continue to underpin the clinical-stage biotechnology company's development pathway. Prescient Therapeutics Ltd, the Melbourne-based clinical-stage biotechnology company developing a novel cancer therapy ca...
Prescient Therapeutics targets cancer with world-first GGTase-1 inhibitor
Prescient is at the forefront of targeted cancer treatment with its lead drug candidate PTX-100, the world’s first GGTase-1 inhibitor ... Read More The post Prescient Therapeutics targets cancer with world-first GGTase-1 inhibitor appeared first on Stockhead.
Prescient Share Purchase Plan Investor Presentation
capital_raise announcement
Prescient Therapeutics Opens SPP to Raise $7m Today
other announcement
Prescient Therapeutics Launches Share Purchase Plan for $7m
capital_raise announcement
Google NewsPrescient Therapeutics (ASX:PTX) trial hits 28 patients as cash runway tightens into 2027 - Stocks Down Under
Prescient Therapeutics (ASX:PTX) trial hits 28 patients as cash runway tightens into 2027 Stocks Down Under
Why Prescient Therapeutics (ASX:PTX) Tops Biotech Penny Watchlists
Highlights Prescient Therapeutics is advancing personalised cancer treatments, with its OmniCAR platform designed to give clinicians greater control over CAR-T style therapies. Trial milestones and cash runway remain the dominant forces shaping sentiment toward clinical-stage oncology juniors on the ASX. Immutep's late-stage lung cancer combination study has passed the halfway mark of enrolment, while PolyNovo anchors the device end of healthcare watchlists. What keep...
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation - simplywall.st
Here's Why We're Not Too Worried About Prescient Therapeutics' (ASX:PTX) Cash Burn Situation simplywall.st
Top Smallcap Stocks to Watch: Prescient Therapeutics (ASX:PTX) Leads the Proof Test
Highlights ASX Smallcap Stocks are attracting closer scrutiny as markets favour evidence, resilience and disciplined execution over broad thematic excitement. Prescient Therapeutics (ASX:PTX) and ECS Botanics (ASX:ECS) illustrate how healthcare and cannabis-focused small caps are being assessed through quality, funding strength and operational progress. Sector rotation, global uncertainty and changing market leadership are encouraging closer att...
ASX Preview: Can Prescient Therapeutics (ASX:PTX) and Renascor Resources (ASX:RNU) Lead Penny Stocks Today?
Highlights Australian shares are expected to begin the session with penny stocks attracting renewed attention as investors become increasingly selective about speculative opportunities. Companies demonstrating stronger cash discipline, funding certainty and credible operational progress are emerging as market favourites. Prescient Therapeutics Ltd (ASX:PTX), Renascor Resources Ltd (ASX:RNU), ECS Botanics Holdings Ltd (ASX:ECS) and Sayona Mining Ltd (ASX:SYA) are expec...
PTX Dr Rosalind Wilson appointed as Chief Medical Officer
other announcement
PTX Trial Momentum Builds as Oncology Pipeline Expands
Highlights PTX-100 clinical program advances with broader global reach Patient enrolment strengthens across key regions Cell therapy platforms continue strategic progress Prescient Therapeutics is advancing its oncology pipeline with steady clinical progress, expanding global trial presence, and continued development across innovative cell therapy platforms. Expanding Clinical Footprint Drives Momentum Prescient Therapeutics Ltd (ASX:PTX) continues to strengthen its position within the ...
PTX secures EU Authorisation to commence PTX-100 Trial
other announcement
PTX secures EU Orphan Drug Designation for PTX-100 in CTCL
other announcement
Completion of Share Placement & s708A Cleansing Notice
capital_raise announcement
Share Placement Progress and Cleansing Notice
capital_raise announcement
Prescient successfully completes $3 million Placement
capital_raise announcement
Prescient announces results of SPP & Launches Placement
capital_raise announcement
Prescient Therapeutics - Extension of Share Purchase Plan
capital_raise announcement